Healthify, the Indian digital health and wellness startup that began life as a calorie-tracking app, is now narrating a different kind of transformation story—one that swaps “growth in India” as the headline for “scale in the US” as the main act. In a candid read on where the business is really headed, co-founder and CEO Tushar Vashisht says the quiet part out loud: the United States isn’t just a market to test anymore—it’s becoming the company’s core focus, the place where revenue is expected to truly stack.

Today, the US business is still modest at around $2 million in annual recurring revenue (ARR), but the ambition is aggressive: double-digit millions by next year, and by 2027, the US should be Healthify’s main revenue generator. That’s not a “let’s see” plan. That’s a reallocation-of-resources plan—engineering, product, research costs—the whole machine turning toward one geography.

The Big Tailwind: The World Is Tracking What It Eats

This shift isn’t happening in a vacuum. Diet, nutrition, and weight management have moved from “nice-to-have” lifestyle habits into a mainstream consumer and healthcare focus. Globally, nutrition and diet apps are growing fast, with the market valued at $2.14 billion in 2024 and projected to reach $4.56 billion by 2030, driven by a 13.4% CAGR.

In plain terms: people are increasingly willing to quantify food, measure outcomes, and pay for guidance—especially when that guidance feels personalized, intelligent, and easy to stick with. And that last word—stick—is where most wellness apps struggle. Healthify is betting that a mix of coaching, clinical credibility, and reimbursement pathways can make engagement less of a grind and more of a system.

Why the US? Because in America, “Wellness” Has a Billing Code

If India is a volume-and-value market, the US is a reimbursement market. That single difference shapes everything.

Healthify’s US strategy leans hard into partnerships with insurance providers and companies that enable reimbursement for registered dieticians (RDs). The logic is simple and powerful: if a user can access dietician support and have it covered by insurance, Healthify’s offering becomes less like an app subscription and more like a healthcare benefit.

That’s why Vashisht points to partnerships as the growth engine: collaborations where registered dieticians are provided as a service, and the insurance provider pays. In the US healthcare system, preventive health isn’t just an idea—it’s increasingly a budget line.

Consulting voices echo the rationale. With preventive health rising globally, weight management and nutrition become a high-urgency category, making dietician collaborations both outcome-improving and monetizable inside the US system.

The Ecosystem Healthify Wants to Plug Into

Healthify isn’t building in isolation—it’s stepping into a US market where dietician-led startups are also racing to scale.

• Berry Street, a dietician startup, raised $50 million in a Series B round earlier this year.
• Fay also raised $50 million, reportedly at a $500 million valuation.

This matters because it signals something important: the market isn’t just about calorie counters anymore. It’s about services, clinical networks, and distribution—often through employers and insurers. Healthify’s approach mirrors this: the app is the interface, but partnerships are the pipeline.

Freemium at the Top, Clinical Depth at the Bottom

Healthify still follows the familiar consumer playbook: a freemium model that draws users in with free features and nudges upgrades through premium layers. Since entering the US, the company says it has tens of thousands of users, with thousands paying.

But the product story is broadening beyond tracking:

• It soft-launched in the US with Snap, its calorie-counting tool.
• It launched an AI-assisted coaching programme in March.
• It rolled out an AI-assisted continuous glucose monitoring (CGM) offering in August.
• Its full software platform is going live this month.
• And it plans to bring HealthifyRx, its premium weight loss programme, to the US as well.

Read between the lines and you see the blueprint: keep the friction low at the top of the funnel, then deepen the experience with coaching, biomarkers, and dietician support—features that feel closer to healthcare than “fitness app.”

India’s Strategy: Pharma First, Providers Next, Insurance Later

Back home, the ladder looks different. In India, Healthify is prioritizing partnerships with pharmaceutical companies, then healthcare providers, with insurance near the bottom of the list. That ordering reflects India’s current healthcare economics: insurance isn’t the universal distribution mechanism it is in the US, but pharma—especially in obesity and metabolic health—is booming.

Healthify has already announced a partnership with Novo Nordisk for a patient assistance programme in India. And the context here is explosive: GLP-1 drugs (the weight-loss and metabolic class that mimics the GLP-1 hormone to influence appetite and blood sugar) are reshaping obesity treatment globally.

• Goldman Sachs projects the global GLP-1 market could hit $95 billion by 2030.
• India’s anti-obesity drug market has grown from ₹133 crore (March 2021) to ₹576 crore (March 2025).
• The category is currently led by Eli Lilly’s tirzepatide (Mounjaro) and Novo Nordisk’s semaglutide (Wegovy).
• The momentum is so intense that Mounjaro reportedly became the top-selling drug brand in India in October, with ₹100 crore monthly sales.

Even more disruptive: semaglutide’s patent exclusivity is expected to end around March 2026, which could trigger cheaper generics from Indian pharma players—expanding access, volume, and the number of users who need support systems around these medications.

Healthify is positioning itself as that support layer: not just “count your calories,” but “navigate your treatment.”

Profitability Isn’t a Footnote—It’s the Plot

What makes this strategy sharper is that the company isn’t talking only about growth—it’s talking about financial discipline.

Vashisht indicates Healthify expects to be cash flow positive next year, and is aiming for a public listing in the next 2–3 years, but only if it can reach high revenue and strong profitability—even “hundreds of millions in revenue,” as a target ambition.

And there’s a key tension here that industry observers underline: if the model works in the US (a high-cost market), it must still remain viable in India (a price-sensitive one). That means outcomes and engagement can’t be decorative metrics. They have to be durable—because in both markets, long-term credibility comes from results people can feel, track, and sustain.

Conclusion: A Two-Market Company, Two Different Engines

Healthify’s story is starting to look like a deliberate split-screen:

• In the US, the company is building around insurance reimbursement, dietician networks, and premium programs—a path designed for higher revenue per user and more institutional distribution.
• In India, it’s aligning with the pharma-driven obesity wave, aiming to become the ongoing support layer for a fast-expanding GLP-1 ecosystem, while keeping profitability as the north star.

If this works, Healthify won’t just be an Indian startup expanding abroad—it’ll be an Indian-born platform learning to operate like a global healthcare business: clinical enough for reimbursement, consumer-friendly enough for scale, and disciplined enough for public markets.

Takeaways

• Healthify is reallocating major resources to make the US its core market, targeting it as the primary revenue driver by 2027.
• US growth hinges on insurance and dietician reimbursement partnerships, not just app subscriptions.
• India growth is tied to pharma collaborations and the GLP-1/anti-obesity boom, where patient support is becoming a major opportunity.
• The company is aiming for cash flow positivity next year and an IPO in 2–3 years, but only alongside strong profitability.
• The real long-term advantage will come from measurable outcomes and sustained engagement, not just downloads.

Feel free to share your experiences and insights in the comments below. Let’s continue the conversation and grow together as a community of traders and analysts.

By sharing this experience and insights, I hope to contribute to the collective knowledge of our professional community, encouraging a culture of strategic thinking and informed decision-making.

As always, thorough research and risk management are crucial. The dynamic nature of financial markets demands vigilance, agility, and a deep understanding of the tools at your disposal. Here’s to profitable trading and navigating the election season with confidence!

Ready to stay ahead of market trends and make informed investment decisions? Follow our page for more insights and updates on the latest in the financial world!

For a free online stock market training by Yogeshwar Vashishtha (M.Tech IIT) this Saturday from 11 am – 1 pm, please sign up with https://pathfinderstrainings.in/training/freetrainings.aspx

Experience profits with my winning algo strategies – get a free one-month trial with ₹15 lakh capital! – https://terminal.algofinders.com/algo-terminal

Disclaimer

This article should not be interpreted as investment advice. For any investment decisions, consult a reputable financial advisor. The author and publisher are not responsible for any losses incurred by investors or traders based on the information provided.